West Pharma (WST) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
West Announces Fourth-Quarter and Full-Year 2016 Results and Announces Quarterly Dividend
February 16, 2017 7:01 AM ESTEXTON, Pa., Feb. 16, 2017 /PRNewswire/ --Â West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2016 and provided detailed financial guidance for full-year 2017.Â
Executive Summary
Fourth-quarter 2016 reported net sales of $382.3 million grew 6.3% over the prior-year quarter. At constant currency, organic sales growth was 7.7%. Full-year 2016 reported net sales of $1.509 billion grew 7.8% over the prior year. At constant currency, organic sales growth was 9.1%. Fourth-quarter 2016 reported diluted EPS was $0.52 as compared to $0.45 in the prior-year... More